TENZOFTALM for normal eye pressure x 30 sachets
TENZOFTALM / TENZOFTALM with palmitoylethanolamide for normal eye pressure
Tenzophthalm is a special formula based on the natural compound palmitoylethanolamide (PEA), which regulates the activity of cells of the nervous and immune systems and physiologically contributes to the maintenance of normal eye pressure.
Palmitoylethanolamide is a substance naturally produced by our body, discovered more than 50 years ago and attracted the attention of medical science for its powerful anti-inflammatory, antioxidant, and cell-protective properties.
Subsequently, its complex role in a number of physiological processes related to metabolism, immune and neural function was established. Today, as a result of dozens of scientific studies, it has been established that palmitoylethanolamide helps to:
· Improving the ability of intraocular fluid to drain.
· Regulation of eye pressure.
· Reducing discomfort and eye strain.
Ingredients (in 1 sachet):
Palmitoylethanolamide: 600 mg
Other ingredients:
Sorbitol (sweetener). Free of allergens and GMOs.
Recommended dosage and method of use:
Take 1 (one) sachet of Tenzoftalm per day. Pour the contents of the sachet directly into the mouth.
Packaging: 30 sachets, enough for a 30-day supply
Why is maintaining normal eye pressure important?
Normal values of intraocular pressure range from 10 to 22 mmHg, with a value above 22 mmHg being referred to as “ocular hypertension,” “ocular hypertension,” or “high eye pressure.” High eye pressure is a risk factor for developing glaucoma, which is the second most common cause of blindness after cataracts.
Short-term changes in intraocular pressure can occur with drinking large amounts of fluids in a short time, lifting weights, consuming alcohol, caffeine, or vomiting. They are usually not dangerous.
A persistent increase in intraocular pressure can occur for a number of reasons, including increased secretion and/or impaired drainage of intraocular fluid.
Diagnosing this problem is done through tonometry, but certain symptoms may signal its presence, for example:
· Eye pain
Blurred vision
· Appearance of light circles
· Sensation of "flies" in the field of vision
Headache
Redness of the eyes
Swelling around the eyes
· Tearing
Sensitivity to light
· Spasm of the eye muscles causing temporary complete or partial closure of the eyelid
The search for new and gentle therapeutic approaches for high intraocular pressure reveals the significant potential of the anti-inflammatory compound palmitoylethanolamide (PEA), whose levels are reduced in the ocular tissues (ciliary body) of glaucoma patients (Chen et al., 2005). On the other hand, it has been found that, when taken additionally, PEA has a two-way regulatory effect on the volume of intraocular fluid – it reduces production and stimulates its outflow (Lindner et al., 2023).
One of the first clinical trials of the substance in patients with high eye pressure and glaucoma found that daily intake of 600 mg of PEA for 2 months resulted in a 16% reduction in intraocular pressure. This effect is comparable to the effect of some currently used drugs for ocular hypertension. An additional positive is that no adverse reactions were recorded as a result of taking PEA during the trial (Gagliano et al., 2011).
In 40 previously untreated patients with ocular hypertension, 3 months of daily administration of 600 mg of palmitoylethanolamide improved blood vessel function and lowered intraocular pressure. Follow-up of patients after the end of the study showed that the positive effect lasted longer than the period of administration, and adverse events were absent (Strobbe, Cellini & Campos, 2013).
Similar findings were observed with longer-term administration of palmitoylethanolamide. Costagliola et al. found that 600 mg of PEA administered for 6 months significantly reduced intraocular pressure and also improved visual field indices in patients with normal tension glaucoma. No ocular or systemic side effects were reported in the study (Costagliola et al., 2014).
It has been found that adding PEA to the current therapy of patients with primary open-angle glaucoma or normal intraocular pressure glaucoma for a period of 4 months has an additional reduction in intraocular pressure. PEA intake contributes to reducing blood vessel damage and weakening the inflammatory process (Rossi et al., 2020).
It has also been found that PEA administration within just 15 days before bilateral laser iridotomy controls the inflammatory process and prevents the expected postoperative increase in intraocular pressure (Pescosolido et al., 2011). There is also evidence that PEA suppresses inflammation and protects ocular tissue in uveitis (Impellizzeri et al., 2015).
Warnings: Tenzophthalm is a food supplement and should not be used as a substitute for a varied diet and a healthy lifestyle. Do not exceed the recommended daily dose. Do not take during pregnancy, lactation and children under 6 years of age. Do not use in case of hypersensitivity to any of the ingredients. Persons taking medication should consume the product only under medical supervision. Excessive consumption may cause a laxative effect due to the sorbitol content. This product contains natural ingredients, therefore there may be a variation or change in the color of the contents of the sachet, which should not be a cause for concern.
Storage conditions: Keep out of reach of small children. Store in a dry place at room temperature.
Manufacturer: Plantapol, Poligono Industrial Los Royales altos C/G 14 50171 La puebla de Alfindén, Zaragoza, Spain
Distributor: "Naturpharma Bulgaria" EOOD Sofia, 21 Yanko Sofiyski Str., tel: +35929633359
